In recent years, the conversation around antidepressants, especially selective serotonin reuptake inhibitors (SSRIs), has evolved significantly. Deprescribing, or the planned and supervised reduction of medication doses, has become an important consideration for many individuals and healthcare providers. Opening this dialogue is essential because SSRIs, though beneficial for many, can sometimes lead to long-term side effects or dependency issues if not managed carefully. From a personal perspective, I've seen friends and family members struggle with the decision to taper off SSRIs. The process isn't simple—there can be withdrawal symptoms, emotional challenges, and concerns about relapse. Yet, with appropriate medical guidance and a strong support system, deprescribing can significantly improve quality of life. This makes Robert F. Kennedy Jr.'s efforts to bring this topic into mainstream political discussion so timely and impactful. Critically, the phrase "trust the science" often used in debates around SSRIs, reminds us that while scientific evidence supports their effectiveness for treating depression and anxiety, it also recognizes the need for ongoing research and individualized treatment plans. Political dialogues involving Democrats and Republicans acknowledging these complexities foster better public understanding and encourage healthcare policies that prioritize patient safety and choice. Incorporating conversations from a political angle helps reduce stigma and promotes greater transparency regarding mental health treatments. It also opens doors to exploring alternative therapies and personalized approaches in psychiatry. Ultimately, deprescribing SSRIs should be a shared conversation among patients, healthcare providers, and policymakers, ensuring that decisions are informed, respectful, and centered on the well-being of those affected.